L&C Bio Co (290650.KQ) Stock Price

L&C Bio Co Price

KOSDAQ·CLOSED
24,600.00
​
Market closed

Over the last 10 years L&C Bio Co grew revenue by 25.2% annually, reaching 85.48 B KRW. Earnings per share have grown at 63.1% per year over the last 9 years. For L&C Bio Co, the net margin of -161.7% is down versus 30.2% a few years ago. At today's price the dividend yield works out to roughly 0.10%. The dividend has grown at 7.0% per year over the past 6 years.

L&C Bio Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

L&C Bio Co business model & stock analysis

L&C BIO Co., Ltd. generates revenue by manufacturing and selling human tissue transplant materials designed for tissue repair and filler applications. The company also produces and sells human tissue-based medical devices and Cosmeceuticals, which serve various surgical needs including vascular, plastic, and general surgeries. The firm operates as a developer of soft tissue, allografts, and medical devices, with its products utilized in multiple medical procedures. This business model focuses on providing essential biological materials and devices to the healthcare sector through its core product lines.

Frequently asked questions about L&C Bio Co

5 analysts currently rate the L&C Bio Co stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect L&C Bio Co to generate revenue of 169.07 B KRW and earnings per share of 207.85 KRW.

Converted at the current exchange rate, the L&C Bio Co share trades at 16.28 EUR (24,600.00 KRW).

The L&C Bio Co share (290650.KQ) is listed on 1 stock exchanges, including: KOSDAQ (Seoul) (290650.KQ).

The expected revenue of L&C Bio Co is 169.07 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of L&C Bio Co is 5.05 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of L&C Bio Co is currently 118.36. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the L&C Bio Co stock.

The price-to-sales ratio (P/S) of L&C Bio Co is currently 3.54. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the L&C Bio Co stock.

The Eulerpool Quality Score for L&C Bio Co is 6/10.

The ISIN of L&C Bio Co is KR7290650001. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of L&C Bio Co is 290650.KQ. The ticker symbol is used to trade L&C Bio Co shares on the stock exchange.

Fair ValueTerminal
25,092.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website lncbio.co.kr
Country
South Korea
Currency
KRW
Initial public offering
Nov 1, 2018
ISIN
KR7290650001
Cusip
Y5S081101
Market capitalization
619.70 B KRWMega Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
122.61
P/Ee 2029
—
P/S
P/Se
3.54
EV/EBIT
134.26
P/B Ratio
3.13
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-68.32 %
Dividend
Dividend yield
0.10 %
Est. Dividend Yield
0.10 %
Payout Ratio
-0.43 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
7 years
Dividend not reduced since
1 year
Dividend increased since
0 years
Dividend withholding tax
22.00 %
Last updated Nov 6, 2026, 3:33 AM

L&C Bio Co Peer Group

L&C Bio Co Ticker

KOSDAQ · 290650.KQ

L&C Bio Co FIGI

290650:KS · BBG00JDLQX15290650:KQ · BBG00LX74Q18

All fundamentals and in-depth analysis of L&C Bio Co

Our stock analysis for L&C Bio Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of L&C Bio Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.